Heritage Investors Management Corp Reduces Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Heritage Investors Management Corp decreased its position in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 4.1% during the fourth quarter, Holdings Channel.com reports. The fund owned 118,369 shares of the company’s stock after selling 5,090 shares during the quarter. Heritage Investors Management Corp’s holdings in Takeda Pharmaceutical were worth $1,689,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of TAK. Apollon Wealth Management LLC bought a new stake in Takeda Pharmaceutical in the fourth quarter worth $219,000. Vestmark Advisory Solutions Inc. increased its holdings in Takeda Pharmaceutical by 2.0% in the 4th quarter. Vestmark Advisory Solutions Inc. now owns 64,920 shares of the company’s stock worth $926,000 after acquiring an additional 1,290 shares in the last quarter. Summit Global Investments lifted its stake in shares of Takeda Pharmaceutical by 0.6% during the 4th quarter. Summit Global Investments now owns 338,415 shares of the company’s stock valued at $4,829,000 after buying an additional 2,091 shares in the last quarter. Van ECK Associates Corp grew its position in shares of Takeda Pharmaceutical by 3.6% during the fourth quarter. Van ECK Associates Corp now owns 1,323,916 shares of the company’s stock worth $18,892,000 after purchasing an additional 45,616 shares in the last quarter. Finally, Headlands Technologies LLC bought a new stake in shares of Takeda Pharmaceutical during the fourth quarter valued at approximately $85,000. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Price Performance

Shares of TAK stock traded up $0.32 during trading hours on Thursday, hitting $13.38. The stock had a trading volume of 2,941,880 shares, compared to its average volume of 1,792,912. The stock has a market capitalization of $42.35 billion, a price-to-earnings ratio of 20.26, a PEG ratio of 3.05 and a beta of 0.56. Takeda Pharmaceutical Company Limited has a one year low of $12.77 and a one year high of $17.03. The stock’s 50-day moving average price is $13.82 and its two-hundred day moving average price is $14.09. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.06 and a quick ratio of 0.55.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.